A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Netarsudil (Rhopressa)

RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

First FDA approval2017-12-18
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$250.3M in CY2024 Part D spend524K claims · 158K beneficiaries · 329 plans surveyed

Lowest NADAC
$131.92/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$131.92
Across all dosage forms in distribution.
Highest NADAC
$131.92
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Netarsudil used for?

RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Is there a generic for Netarsudil?

No. Netarsudil is brand-only with no generic equivalents currently in market.

How much does my plan pay for Netarsudil?

Across 329 Part D plans, Netarsudil averages $131.92/unit (NADAC). Lowest available: $131.92/unit. Highest in distribution: $131.92/unit.

Is Netarsudil on the FDA shortage list?

No. Netarsudil is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.